These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 17669435)
1. Implications of partial immunity on the prospects for tuberculosis control by post-exposure interventions. Gabriela M Gomes M; Rodrigues P; Hilker FM; Mantilla-Beniers NB; Muehlen M; Cristina Paulo A; Medley GF J Theor Biol; 2007 Oct; 248(4):608-17. PubMed ID: 17669435 [TBL] [Abstract][Full Text] [Related]
2. Modelling the effects of pre-exposure and post-exposure vaccines in tuberculosis control. Bhunu CP; Garira W; Mukandavire Z; Magombedze G J Theor Biol; 2008 Oct; 254(3):633-49. PubMed ID: 18644386 [TBL] [Abstract][Full Text] [Related]
3. Heterogeneity in susceptibility to infection can explain high reinfection rates. Rodrigues P; Margheri A; Rebelo C; Gomes MG J Theor Biol; 2009 Jul; 259(2):280-90. PubMed ID: 19306886 [TBL] [Abstract][Full Text] [Related]
5. A model for tuberculosis with exogenous reinfection. Feng Z; Castillo-Chavez C; Capurro AF Theor Popul Biol; 2000 May; 57(3):235-47. PubMed ID: 10828216 [TBL] [Abstract][Full Text] [Related]
6. The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis. Derrick SC; Perera LP; Dheenadhayalan V; Yang A; Kolibab K; Morris SL Vaccine; 2008 Nov; 26(48):6092-8. PubMed ID: 18809446 [TBL] [Abstract][Full Text] [Related]
7. Infection, reinfection, and vaccination under suboptimal immune protection: epidemiological perspectives. Gomes MG; White LJ; Medley GF J Theor Biol; 2004 Jun; 228(4):539-49. PubMed ID: 15178201 [TBL] [Abstract][Full Text] [Related]
8. Impact of HIV on novel therapies for tuberculosis control. Sánchez MS; Lloyd-Smith JO; Porco TC; Williams BG; Borgdorff MW; Mansoer J; Salomon JA; Getz WM AIDS; 2008 May; 22(8):963-72. PubMed ID: 18453856 [TBL] [Abstract][Full Text] [Related]
9. Update on the treatment of tuberculosis. Inge LD; Wilson JW Am Fam Physician; 2008 Aug; 78(4):457-65. PubMed ID: 18756652 [TBL] [Abstract][Full Text] [Related]
10. [Evolution of IGRA researches]. Ariga H; Harada N Kekkaku; 2008 Sep; 83(9):641-52. PubMed ID: 18979999 [TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics of tuberculosis in childhood]. Herranz M; Bernaola E An Sist Sanit Navar; 2007; 30 Suppl 2():117-29. PubMed ID: 17898832 [TBL] [Abstract][Full Text] [Related]
12. Optimal control for a tuberculosis model with reinfection and post-exposure interventions. Silva CJ; Torres DF Math Biosci; 2013 Aug; 244(2):154-64. PubMed ID: 23707607 [TBL] [Abstract][Full Text] [Related]
13. Tuberculosis transmission model with chemoprophylaxis and treatment. Bhunu CP; Garira W; Mukandavire Z; Zimba M Bull Math Biol; 2008 May; 70(4):1163-91. PubMed ID: 18231839 [TBL] [Abstract][Full Text] [Related]
14. Preventive chemotherapy. Where has it got us? Where to go next? Landry J; Menzies D Int J Tuberc Lung Dis; 2008 Dec; 12(12):1352-64. PubMed ID: 19017442 [TBL] [Abstract][Full Text] [Related]
15. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development. Dietrich J; Doherty TM APMIS; 2009 May; 117(5-6):440-57. PubMed ID: 19400867 [TBL] [Abstract][Full Text] [Related]
20. Modelling heterogeneity in host susceptibility to tuberculosis and its effect on public health interventions. Wangari IM; Trauer J; Stone L PLoS One; 2018; 13(11):e0206603. PubMed ID: 30427891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]